The Reviewing Quintiles IMS Holdings (Q) and Roka Bioscience (ROKA)

The Reviewing Quintiles IMS Holdings (Q) and Roka Bioscience (ROKA)

Insider and Institutional Ownership

Roka Bioscience (NASDAQ: ROKA) and Quintiles IMS Holdings (NYSE:Q) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitabiliy, institutional ownership, earnings, dividends and analyst recommendations.

45.9% of Quintiles IMS Holdings shares are held by institutional investors. 28.9% of Roka Bioscience shares are held by company insiders. Comparatively, 10.9% of Quintiles IMS Holdings shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Roka Bioscience and Quintiles IMS Holdings, as provided by MarketBeat.com.

Roka Bioscience currently has a consensus target price of $10.00, indicating a potential upside of 277.36%. Quintiles IMS Holdings has a consensus target price of $83.97, indicating a potential downside of 2.53%. Given Roka Bioscience’s stronger consensus rating and higher possible upside, research analysts plainly believe Roka Bioscience is more favorable than Quintiles IMS Holdings.

Profitability

This table compares Roka Bioscience and Quintiles IMS Holdings’ net margins, return on equity and return on assets.

Volatility & Risk

Roka Bioscience has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, Quintiles IMS Holdings has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.

Valuation and Earnings

This table compares Roka Bioscience and Quintiles IMS Holdings’ revenue, earnings per share (EPS) and valuation.

Quintiles IMS Holdings has higher revenue and earnings than Roka Bioscience. Roka Bioscience is trading at a lower price-to-earnings ratio than Quintiles IMS Holdings, indicating that it is currently the more affordable of the two stocks.

Summary

Quintiles IMS Holdings beats Roka Bioscience on 8 of the 13 factors compared between the two stocks.

Roka Bioscience Company Profile

Roka Bioscience, Inc. is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.

Quintiles IMS Holdings Company Profile

Quintiles IMS Holdings, Inc., formerly Quintiles Transnational Holdings Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.

Related posts

Leave a Comment